Compare SNDL & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDL | DNA |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | Canada | United States |
| Employees | N/A | 485 |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.0M | 455.8M |
| IPO Year | 2019 | N/A |
| Metric | SNDL | DNA |
|---|---|---|
| Price | $1.46 | $8.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.19 | N/A |
| Revenue Next Year | $3.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $5.37 |
| 52 Week High | $2.89 | $17.58 |
| Indicator | SNDL | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 47.31 |
| Support Level | $1.45 | $7.59 |
| Resistance Level | $1.50 | $9.58 |
| Average True Range (ATR) | 0.05 | 0.76 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 69.23 | 30.18 |
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.